Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function

Lomon So; Sung Su Yea; Jean S. Oak; Mengrou Lu; Arun Manmadhan; Qiao Han Ke; Matthew R. Janes; Linda V. Kessler; Jeff M. Kucharski; Lian Sheng Li; Michael B. Martin; Pingda Ren; Katti A. Jessen; Yi Liu; Christian Rommel; David A. Fruman

doi:10.1074/jbc.M112.379446

Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function

Lomon So, Sung Su Yea, Jean S. Oak, Mengrou Lu, Arun Manmadhan, Qiao Han Ke, Matthew R. Janes, Linda V. Kessler, Jeff M. Kucharski, Lian Sheng Li, Michael B. Martin, Pingda Ren, Katti A. Jessen, Yi Liu, Christian Rommel, David A. Fruman

Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.

Original language	English (US)
Pages (from-to)	5718-5731
Number of pages	14
Journal	Journal of Biological Chemistry
Volume	288
Issue number	8
DOIs	https://doi.org/10.1074/jbc.M112.379446
State	Published - Feb 22 2013

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1074/jbc.M112.379446

Cite this

So, L., Yea, S. S., Oak, J. S., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L. V., Kucharski, J. M., Li, L. S., Martin, M. B., Ren, P., Jessen, K. A., Liu, Y., Rommel, C., & Fruman, D. A. (2013). Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function. Journal of Biological Chemistry, 288(8), 5718-5731. https://doi.org/10.1074/jbc.M112.379446

@article{fed6bd83d0144d2faac5d7e765e7b393,

title = "Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function",

abstract = "Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.",

author = "Lomon So and Yea, {Sung Su} and Oak, {Jean S.} and Mengrou Lu and Arun Manmadhan and Ke, {Qiao Han} and Janes, {Matthew R.} and Kessler, {Linda V.} and Kucharski, {Jeff M.} and Li, {Lian Sheng} and Martin, {Michael B.} and Pingda Ren and Jessen, {Katti A.} and Yi Liu and Christian Rommel and Fruman, {David A.}",

year = "2013",

month = feb,

day = "22",

doi = "10.1074/jbc.M112.379446",

language = "English (US)",

volume = "288",

pages = "5718--5731",

journal = "Journal of Biological Chemistry",

issn = "0021-9258",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "8",

}

TY - JOUR

T1 - Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function

AU - So, Lomon

AU - Yea, Sung Su

AU - Oak, Jean S.

AU - Lu, Mengrou

AU - Manmadhan, Arun

AU - Ke, Qiao Han

AU - Janes, Matthew R.

AU - Kessler, Linda V.

AU - Kucharski, Jeff M.

AU - Li, Lian Sheng

AU - Martin, Michael B.

AU - Ren, Pingda

AU - Jessen, Katti A.

AU - Liu, Yi

AU - Rommel, Christian

AU - Fruman, David A.

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.

AB - Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.

UR - http://www.scopus.com/inward/record.url?scp=84874301974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874301974&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.379446

DO - 10.1074/jbc.M112.379446

M3 - Article

C2 - 23275335

AN - SCOPUS:84874301974

SN - 0021-9258

VL - 288

SP - 5718

EP - 5731

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

IS - 8

ER -

Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this